Iovance Biotherapeutics Earnings Call: Key Takeaways
Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.
- Call
- Nov 5, 2026, 8:30 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Iovance Biotherapeutics, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
2 alerts with these filters
Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.
Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.